(Q35142948)

6 August 2017

1 reference

title

The clinical use of gabapentin in bipolar spectrum disorders (English)

1 reference

6 August 2017

0 references

1 reference

Heinz Grunze

4

0 references

author name string

Mauro Giovanni Carta

1

1 reference

6 August 2017

Maria Carolina Hardoy

2

1 reference

6 August 2017

Maria Julieta Hardoy

3

1 reference

6 August 2017

Bernardo Carpiniello

5

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Journal of Affective Disorders

6 August 2017

published in

1 reference

6 August 2017

volume

75

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

83-91

1 reference

Gabapentin in the acute treatment of refractory bipolar disorder.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin for treatment of bipolar and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Rebound psychiatric and physical symptoms after gabapentin discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

An open label study of gabapentin in the treatment of acute mania.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin treatment of mood disorders: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Novel anticonvulsants: a new generation of mood stabilizers?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

[Gabapentin in the treatment of mania].

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Hypomania induced by gabapentin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin as monotherapy in the treatment of acute mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin. Antiepileptic mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin leads to remission of somatoform pain disorder with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin treatment for insomnia associated with alcohol dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin in the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Hypomania induced by gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Treatment of acute mania with gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin in the treatment of adolescent mania: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

A summary of mechanistic hypotheses of gabapentin pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Adjunctive gabapentin treatment of bipolar disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Acute treatment of bipolar depression with gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

Gabapentin as an adjunctive treatment in bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900046-0

7 January 2021

10.1016/S0165-0327(02)00046-0

Identifiers

DOI

1 reference

6 August 2017

1 reference